Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2021-09-17 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于为控股及全资子公司提供担保进展情况的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 瑞康医药集团股份有限公司 regarding the progress of guarantees provided for its controlling and wholly-owned subsidiaries. It details the guarantee amounts, types, related financial institutions, and financial status of the guaranteed subsidiaries. The document includes specific financial figures related to guarantees but does not present a comprehensive financial report or earnings release. It is a regulatory announcement about financing guarantees rather than a full financial report or earnings announcement. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities related to guarantees provided to subsidiaries.
2021-09-17 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is a statement by the independent directors of 瑞康医药集团股份有限公司 regarding related party fund occupation and external guarantees. It references regulatory notices from the China Securities Regulatory Commission and company internal rules. The document is a special explanation and independent opinion on these matters, signed by all independent directors. It does not contain financial statements or detailed financial data, nor is it an announcement of a meeting or voting results. It is a standalone audit-related opinion on specific compliance and risk control issues, fitting the definition of an Audit Report / Information (AR). The document length is short (909 characters), but it contains substantive content rather than just an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence. H1 2021
2021-08-30 Chinese
2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2021 半年度报告摘要' which translates to '2021 Half-Year Report Summary'. It contains detailed financial data and performance metrics for the half-year period, including revenue, net profit, earnings per share, and shareholder information. The document is a summary of the half-year report, which is a type of interim or quarterly report. It is not merely an announcement or a certification, but contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is 3321 characters, which is sufficient for a summary report and not just a brief announcement. Hence, the classification is IR with high confidence. H1 2021
2021-08-30 Chinese
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolution passed at the 15th meeting of the 4th Supervisory Board of Ruikang Medical Group Co., Ltd. It specifically mentions the approval of the company's 2021 semi-annual report and its summary. The document states that the report complies with relevant laws and regulations and reflects the company's operating status for the half-year period. However, the document itself is a meeting resolution announcement and does not contain the actual semi-annual report or detailed financial data. The document length is short (608 characters), and it serves as an official announcement of the approval of the interim report rather than the report itself. Therefore, according to the MENU VS MEAL RULE, this should be classified as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR).
2021-08-30 Chinese
半年报董事会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 16th meeting of the 4th Board of Directors of Ruikang Medical Group Co., Ltd. It includes approval of the company's 2021 semi-annual report and a proposal regarding accounts receivable asset securitization. The document contains voting results and details about the board meeting but does not include the full semi-annual report itself or detailed financial statements. The document length is short (1489 characters) and it serves as a formal announcement of board decisions rather than the report itself. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-08-30 Chinese
2021年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2021 年半年度财务报告" which translates to "2021 Half-Year Financial Report". It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, notes on accounting policies, and other comprehensive financial data for the half-year period ending June 30, 2021. The report explicitly states it is a half-year report and includes substantive financial data and analysis, not just an announcement or summary. It is not an annual report (10-K) but an interim/quarterly report covering a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.